Q4 2020 Earnings

Revenue

$57M+19.4% YoY

Gross Profit

$33M57.1% margin

Operating Income

$331,0000.6% margin

Net Income

-$4M-6.3% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

+8.1%

Operating Cash Flow

-$6M

Free Cash Flow

-$8M

Stock-Based Comp.

$2M

Total Assets

$461M

Total Liabilities

$265M

Stockholders' Equity

$196M

Cash & Equivalents

$8M

Metric	Current	Year Ago	Change
Revenue	$57M	$48M	+19.4%
Gross Profit	$33M	$30M	+8.4%
Operating Income	$331,000	-$5M	+107.1%
Net Income	-$4M	-$5M	+24.8%

Sales Of Generic Pharmaceutical Products

$39M68%

Sales Of Branded Pharmaceutical Products

$16M28%

Sales Of Contract Manufactured Products

$2M4%

Royalties From Licensing Agreements

$276,0000%

Other Revenues

$265,0000%

Product Development Services

$107,0000%

$56M98%

$973,0002%